A draft of the new International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD), designed to be a supportive decision-making tool in the management of these patients, will be released in late March 2022, and a panel of experts at the International Society of Oncology Pharmacy Practitioners (ISOPP) 2022 Virtual Symposium offered a preview of what the oncology community can expect from this guideline.